Immunic, Inc. (IMUX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
IMUX Executes 1-for-10 Reverse Stock Split on April 27
# 🧾 What This Document Is This is an **8-K filing**, a "current report" that companies must file with the SEC to announce major events that shareholders should know about. Immunic is announcing a **1-for-10 reverse stock split** of its common stock. The filing includes the official legal amendment
IMUX files 1-for-10 reverse stock split after shareholder approval
# 📰 What This Document Is 📂 This document is an Amendment No. 1 to Immunic, Inc.'s Annual Report on Form 10-K. Think of a 10-K as the company's comprehensive, required annual report card, and this amendment is like a correction—it's being filed to update and include critical corporate governance i
IMMUNIC, INC. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing, which is a report companies use to announce major news to investors. In this case, Immunic is sharing official notice from Nasdaq that it has fixed a problem and is no longer at risk of being removed from the stock exchange. # 🚨 The Core Announceme
March 2026
IMMUNIC, INC. — 8-K Filing
# 🔖 What This Document Is This is an **8-K filing**, which is a report a company files with the SEC to announce major, shareholder-affecting news. In this case, **Immunic, Inc. (IMUX)** is announcing a key addition to its leadership team. Think of it as a formal press release with regulatory weight
SEC filings
All filings →Insider trades
All insider trades →Immunic, Inc. has no reported insider trades in the last 90 days.